Helen & Sam Steinberg Family Career Scientist
Jewish General Hospital
(514) 340-8222 X 5418
Education: M.D. C.M., McGill University; B.S., Columbia University
Clinical Focus: Novel Therapeutics.
Research Focus: Molecular Pharmacology; Chemoprevention.
Madrid Spain, International Cancer Conference 2014 (IGICC), Sanofi Canada, Feb.21: ICC Conference ‘Meet the Professor’, Feb. 22, Invited Speaker Topic: Q-CROC Biomarker Research: Overview of the Q-CROC platform and objectives; overview of the Q-CROC 01 and 02 studies. Feb.21-22
Toronto, NCIC CTG Workshop, Towards a Pan-Canadian Personalized Medicine Cancer Trials Platform, Speaker, Title “Patient profiling to identify future trial participants”. May 1
Chicago, ASCO-Annual Meeting, Speaker/ GI Consultation Meeting, topic: Overview and Update of QCROC 01-04 molecular biomarker study. May 31-June 3
London,UK, IDBS Connect 2014, Invited Presenter, Topic: Collaboration in Translational Sciences & Personalized Medicine with Dr. Robin Munro, IDBS Video interview at the event: “Industry trends in the lab informatics space and the main challenges researchers are facing today” to be used for internal and external IDBS communications. June 17-19
Paris, WIN 2014 Symposium, Moderator, Plenary Session: Combinations of targeted therapies. June 23-24
Montreal-MNI, Personalized Medicine Conference, Invited on Panel: From Research to Clinical Practice with A Grant, M Leblanc, C Deakin. September 9
Montreal, Palais des Congrès, 20th International Congress on Palliative Care (CPAC), Invited Speaker, Talk: Developing Clinical Indicators in a McGill-Wide Network- The Rossy Cancer Network. September 11
Montreal, Goodman Cancer Centre, McGill-Stem Cell Open Discussion, Invited speaker, title: Stem cells/ Regenerative. Medicine at the JGH/Lady Davis Institute. November 24
Montreal, McGill – 4th Annual Symposium of the Gerald Bronfman Centre for Clinical Research in Oncology, Invited Speaker, title: The ExACCT Program: New paradigms for research and implementation of novel cancer therapeutics. November 24
Henriques L, M Palumbo, MP Guay, B Bahoric, M Basik, P Kavan, G Batist. Title: Imiquimod in the Treatment of Breast Cancer Skin Metastases. J Clin Oncol. 2014 Mar 10;32(8):e22-5. doi: 10.1200/JCO.2012.46.4883. Epub 2014 Jan 13
Oriana Yu, Maria Eberg, Serge Benayoun, Armen Aprikian, Gerald Batist, Samy Suissa, and Laurent Azoulay. Use of statins and risk of death in patients with prostate cancer. J Clin Oncol. 2014 Jan 1;32(1):5-11 doi: 10.1200/JCO.2013.49.4757. Epub 2013 Nov 4.
Chukkapalli S, Amessou M, Kumar Dilly A, Dekhil H, Liu Q, Bandyopadhyay S, Thomas RD, Bejna A, Batist G, Kandouz M, title: Ehd3, a regulator of vesicular trafficking, is silenced in gliomas and functions as a tumor suppressor by controlling cell cycle arrest and apoptosis. Carcinogenesis. 2014 Apr;35(4):877-85. doi: 10.1093/carcin/bgt399. Epub 2013 Dec 4
Chukkapalli S, Amessou M, Kumar Dilly A, Dekhil H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA, Neill D, Azoulay L, Batist G, Kandouz M. Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. Exp Cell Res. 2014 Jan15; 320(2):233-46
Stewart DJ. Batist G.,Title: Redefining cancer: a new paradigm for better and faster treatment innovation. J Popul Ther Clin Pharmacol. 2014;21(1):e56-65. Epub 2014 Feb 23.
Henriques L1, Palumbo M, Guay MP, Bahoric B, Basik M, Kavan P, Batist G., Title Imiquimod in the treatment of breast cancer skin metastasis. J Clin Oncol. 2014 Mar 10;32(8):e22-5. doi: 10.1200/JCO.2012.46.4883. Epub 2014 Jan 13
Ferrario C. Batist G., title Advances in the approach to novel drug clinical development for breast cancer.” Expert Opin Drug Discov. 2014 Jun;9(6):647-68. doi: 10.1517/17460441.2014.911282. Epub 2014 Apr 23.
Vladimir Lazar et al including Gerald Batist, A Simplified Interventional Mapping System (SIMS) for the Selection of Combinations of Targeted Treatments in Non-Small Cell Lung Cancer, OncoTarget, In Press 2015
Eric Paquet, et al including G. Batist A 12-gene panel to identify patients with CRC particularly responsive to Irinotecan adjuvant therapy. Journal of Pathology-Clinical Research, In Press 2015.